BioXcel Therapeutics to Present at ThinkEquity Conference
NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
Neuroscience
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
Linus Health to Demonstrate How Digital Health Powers Innovation at Clinical Trials on Alzheimer’s Disease (CTAD)
Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers...
MIRA Pharmaceuticals’ Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)...
Vitamin K supplement slows prostate cancer in mice
COLD SPRING HARBOR, N.Y., Oct. 24, 2024 /PRNewswire/ -- Prostate cancer is a quiet killer. In most men, it's treatable....
Lin Health to Collaborate with Mayo Clinic to Expand Access to Evidence-Based, Tech-Enabled Chronic Pain Care
Retraining the brain's neural circuitry through a behavioral health approach empowers people living with chronic pain to avoid costly and...
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is...
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is...
Nikon Small World Competition Celebrates 50 Years with Groundbreaking Image of Brain Tumor Cells
Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of...
Linus Health Leader to Join ‘Brainiacs’ Panel at HLTH 2024 to Discuss Advancements in Cognitive Impairment Screening
Company also a finalist for Digital Health Awards to be announced on opening night BOSTON, Oct. 17, 2024 /PRNewswire/ --...
Sarah Sheikh Joins Cerevance’s Board of Directors
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment...
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients...
Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth
MANCHESTER, England, Oct. 15, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment...
Neurophet-AriBio to develop ‘Next-Gen Platform for Alzheimer’s diagnosis’
- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease...
Perceiv AI Welcomes Simona Skerjanec to Board of Directors
Thought Leader in Brain Health Joins Richard Stark and Company Co-Founders to Accelerate Innovation in Precision MedicineMONTREAL, QC / ACCESSWIRE...
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Data selected for oral presentation reinforce previous findings on safety and efficacyMALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics,...
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...